ethyl 7-(4-hydroxy-3-(N-phenylcarbamoyl)phenylamino)-7-oxoheptanoate | 1352440-62-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 7-(4-hydroxy-3-(N-phenylcarbamoyl)phenylamino)-7-oxoheptanoate
• CAS: 1352440-62-0
• 化学式: C₂₂H₂₆N₂O₅
• 分子量: 398.459
• InChiKey: COJXEYNGXMLPGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29.0
• 可旋转键数：
  10.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  104.73
• 氢给体数：
  3.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  ethyl 7-(4-hydroxy-3-(N-phenylcarbamoyl)phenylamino)-7-oxoheptanoate 在 盐酸羟胺 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 以63%的产率得到N-phenyl-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide
  参考文献：
  名称：

  Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors

  摘要：

  A novel series of N-aryl salicylamides with a hydroxamic acid moiety at 5-position were synthesized efficiently. Their activities against EGFR kinase and HDACs were evaluated. All compounds displayed inhibitory activity against EGFR and HDACs. The antiproliferative activities of synthesized compounds were evaluated by MTT method against human cancer cell lines A431, A549 and HL-60. Compound 1o showed the most potent inhibitory activity against A431 and A549. Compounds 1k and 1n exhibited higher potency against HL-60 than gefitinib and SAHA. N-Aryl salicylamides with a hydroxamic acid moiety at 5-position is another new HDAC-EGFR dual inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.034
• 作为产物：
  描述：

  庚二酸氢乙酯 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 ethyl 7-(4-hydroxy-3-(N-phenylcarbamoyl)phenylamino)-7-oxoheptanoate
  参考文献：
  名称：

  Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors

  摘要：

  A novel series of N-aryl salicylamides with a hydroxamic acid moiety at 5-position were synthesized efficiently. Their activities against EGFR kinase and HDACs were evaluated. All compounds displayed inhibitory activity against EGFR and HDACs. The antiproliferative activities of synthesized compounds were evaluated by MTT method against human cancer cell lines A431, A549 and HL-60. Compound 1o showed the most potent inhibitory activity against A431 and A549. Compounds 1k and 1n exhibited higher potency against HL-60 than gefitinib and SAHA. N-Aryl salicylamides with a hydroxamic acid moiety at 5-position is another new HDAC-EGFR dual inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.034